• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of direct data communications with Review/Policy Divisions within CDER (Office of Generic Drugs (OGD), Office of New Drug Quality Assessment (ONDQA), Office of Biotechnology Products (OBP), Office of Compliance (OC), Office of New Drugs (OND), CDER/Immediate Office (IO)) and Office of the Commissioner within the month)

Dictionary: The Office of Testing and Research (OTR) is tracking the number of research summaries, findings, and/or results OTR provides to CDER and other Agency customers.


These measures has been retired as CDER has created new measures for FY13 which align to their four functional areas of 1) Regulatory Review and Drug Safety, 2) Drug Quality and Compliance, 3) Transparency and Public Outreach, and 4) Regulatory Science Research.

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetNumber
Oct 2010N/A30
Nov 2010N/A31
Dec 2010N/A36
Jan 2011N/A120
Feb 2011N/A91
Mar 2011N/A51
Apr 2011N/A39
May 2011N/A30
Jun 2011N/A23
Jul 2011N/A65
Aug 2011N/A62
Sep 2011N/A62

FY 2011 Total: 640

Number of Interim and Final Technical Reports sent to Review/Policy Divisions CDER (OGD, ONDQA, OBP, OC, OND, CDER/IO) and Office of the Commissioner within the month

Dictionary: OTR is tracking the number of technical reports OTR provides to CDER and other Agency customers.

Fiscal Year - 2011

Skip graphic and jump to text data

TimeTargetNumber
Oct 2010N/A6
Nov 2010N/A10
Dec 2010N/A15
Jan 2011N/A17
Feb 2011N/A12
Mar 2011N/A14
Apr 2011N/A24
May 2011N/A24
Jun 2011N/A20
Jul 2011N/A20
Aug 2011N/A19
Sep 2011N/A12

FY 2011 Total: 193

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.